Skip to main content

Emmes Logo

ROCKVILLE, Md., Aug. 12, 2020 /PRNewswire/ — Emmes today announced that it provided the data and statistical analysis support for the Phase 1 clinical trial of the investigational COVID-19 vaccine mRNA-1273.  Three Emmes employees were co-authors on the Preliminary Report about the clinical trial, “An mRNA Vaccine against SARS-CoV-2,” published in the New England Journal of Medicine on July 14.

 

{iframe}https://www.biospace.com/article/releases/emmes-announces-its-role-in-phase-1-covid-19-vaccine-trial/{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.